156 stories across all digests
Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Kumamoto University researchers developed cyclic peptide D-DNP-V that escorts insulin through the gut, achieving one-third to nearly half the effectiveness of injected insulin in mice.
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
Retrospective study found combining CGRP monoclonal antibodies with gepants is a safe and well-tolerated dual-mechanism migraine prevention approach.
Retrospective cohort study showed significant migraine frequency reduction with favorable safety for patients with comorbid MS taking CGRP-targeted treatments.
New data shows GLP-1 adherence drops significantly after the first year, with cost as a major factor. Insurance gaps and lack of mandated weight loss coverage pose barriers.
Kumamoto University researchers developed a cyclic peptide (DNP peptide) that enables oral insulin delivery through the intestinal wall — a dramatic improvement that could end the century-long dependence on injections.
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.
In-depth review examined 544 BPC-157 papers and found only 3 human studies and zero randomized controlled trials. Author recommends most people avoid it until stronger evidence emerges.
A Cleveland Clinic analysis of 7,938 adults who discontinued semaglutide or tirzepatide found that real-world outcomes are better than clinical trials suggested. Obesity patients regained just 0.5% of body weight on average after one year, and 45% either maintained or continued losing weight by restarting treatment, switching medications, or adopting lifestyle changes.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.
A study published in Nature Microbiology used a generative AI approach to discover antimicrobial peptides effective against multidrug-resistant bacteria. The deep learning pipeline screened millions of candidate sequences, achieving a 94.4% success rate in lab validation, with two candidates showing exceptional efficacy and low resistance potential.